Vicinitas Therapeutics Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2022

Location

San Francisco CA US

Primary Industry

Biotechnology

About

Based in California, US, and founded in 2022, Vicinitas Therapeutics operates as a biotechnology company that develops small-molecule drugs. The company was founded by Dan Nomura. In July 2022, Vicinitas Therapeutics raised USD 65 million in series A funding co-led by Andreessen Horowitz, Deerfield Management, Berkeley Catalyst Fund, and DROIA Ventures. Vicinitas Therapeutics offers Deubiquitinase Targeting Chimera (DUBTAC), which is a targeted protein stabilization (TPS) platform that is focused on many diseases that are driven by proteins, which include cancer and monogenic diseases. The company's TPS platform provides development based on heterobifunctional small molecules, which contain an OTUB1 recruiter for the deubiquitinase and a ligand that targets proteins.

Current Investors

GV, Andreessen Horowitz, Deerfield Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.vicinitastx.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.